Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENX-102 in Generalized Anxiety Disorder
NCT06653296Phase 2Completed
- Sponsor
- Engrail Therapeutics
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ENX-102 in generalized anxiety disorder (GAD), sponsored by Engrail Therapeutics. Started Dec 2024; status: completed.
02
Drugs
ENX-102
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT06653296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06653296.